Base business recovers in Q2; FY21 outlook reiterated despite resurfacing COVID-19 concerns
28/07/21 -"On softer comps, Faes witnessed some recovery in the base business in Q2 21. While resurfacing COVID-19 concerns and Bilastine’s recent patent loss in Spain does signal a tricky period ahead, one ..."
Pages
52
Language
English
Published on
28/07/21
You may also be interested by these reports :
26/06/25
Downside for 1H25E consensus – FY25E consensus should be fine – Mid-term potential reiterated
24/06/25
Just like Big Pharmas in aggregate, Sanofi’s (Buy; France) shares have gone nowhere over the last two years. After collapsing by c.19% in a day in ...
12/06/25
Only a month ago we were lamenting the weakness of Pharmas, the second larget sector by market cap. The tide may have turned, strangely as part ...
11/06/25
Faes Farma made a good move to acquire the Italian ophthalmology firm SIFI, whose enterprise value is c.20% of Faes’ market cap. This deal would not ...